Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 22Pancreatic Neoplasms 16Neoplasm Metastasis 9Rectal Neoplasms 5Neuroblastoma 5Neoplasms 5Colonic Neoplasms 5Stomach Neoplasms 4Sarcoma 4Rhabdomyosarcoma 4Lung Neoplasms 4Sarcoma, Ewing 3Cholangiocarcinoma 3Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Medulloblastoma 2Hepatoblastoma 2Glioma 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Bone Neoplasms 2Adenocarcinoma Of Esophagus 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Turcot syndrome 1Solid Cancer 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1

Interventions

trastuzumab deruxtecan 1toripalimab 1pertuzumab 1pembrolizumab 1atezolizumab 1Trastuzumab 1Ramucirumab 1Paclitaxel 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Etoposide 1Cetuximab 1Carboplatin 1Capecitabine 1Bevacizumab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Solid Cancer × Irinotecan × Clear all
NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

FBD Biologics Limited

Phase 1/2 Active not recruiting
500 enrolled

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡